JWJinhong Wei

Jinhong Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinhong Wei has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Sui Rong Wayne Chen

    Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4Z6, Canada

    6 shared publications
  • Wenting Guo

    State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, China

    5 shared publications
  • Ruiwu Wang

    Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, Alberta, Canada (M.N., Y.L., J.W., Z.S., H.W., J.Y., Y.-X.C., D.B., J.P.E., R.W., S.R.W.C.).

    4 shared publications
  • Yanhui Li

    Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, Canada (B.S., M. Ni, Y.L., Z.S., H.W., H.-L.Z., J.W., D.B., S.C., W.G., J.Y., S.T., J.P.E., R.W., S.R.W.C.).

    4 shared publications
  • Alexander Vallmitjana

    Beckman Laser Institute, University of California, Irvin, CA 92617, USA

    3 shared publications
  • Bo Sun

    Department of Physiology and Pharmacology, Libin Cardiovascular Institute University of Calgary Calgary Canada

    3 shared publications

Latest Publications

  • Open Access

    Calcium release deficiency syndrome: an emerging ryanodinopathy

    by Kaiyang Gao, Lan Tao, Xiaoqing Li, Baihe Li, Nike Li, Jinhong Wei

    The cardiac ryanodine receptor (RyR2) is a critical calcium release channel essential for normal cardiac contraction. Dysregulation of RyR2 function is a key pathogenic factor in various cardiac diseases, notably arrhythmias and heart failure. The clinical spectrum of RyR2-related diseases (ryanodinopathy) has expanded beyond the well-established gain-of-function (GOF) mutations causing catecholaminergic polymorphic ventricular tachycardia (CPVT). Recent research has now delineated two additional distinct clinical entities: exon 3 deletion syndrome (E3DS), which presents with CPVT along with structural abnormalities, and calcium release deficiency syndrome (CRDS), caused by loss-of-function (LOF) mutations. CRDS is characterized by impaired calcium release from the sarcoplasmic reticulum and fundamentally differs from the classical CPVT phenotype, necessitating distinct approaches to its diagnosis, clinical management, and therapeutic intervention. This review provides a comprehensive overview of the current understanding of CRDS. We discuss its clinical manifestations, scrutinize the underlying molecular mechanisms, evaluate available diagnostic strategies, and explore potential therapeutic avenues. By synthesizing latest findings, this review aims to illuminate the complexities of RyR2-mediated pathologies and foster further progress in this evolving field.

  • Open Access

    Structural and Functional Regulation of RyR2 in Cardiac Calcium Handling and Arrhythmogenesis

    by Kaiyang Gao, Wenzhuo Wang, Yanan Ling, Baihe Li, Chenlei Xing, Nike Li, Xiaolan Yin, Lan Tao, Xiaoqing Li, Junling Qiu, et al.

    Cardiac Ca2+ handling is critical for excitation–contraction coupling (ECC), with the ryanodine receptor type 2 (RyR2) serving as the key sarcoplasmic reticulum (SR) Ca2+ release channel in cardiomyocytes. The dysfunction of RyR2 is linked to fatal cardiac arrhythmias, including heart failure (HF) and catecholaminergic polymorphic ventricular tachycardia (CPVT). This review aims to elucidate the structural basis of RyR2, its core role in cardiac ECC and Ca2+ homeostasis, and the regulatory mechanisms of key modulators on its activity. By integrating recent high-resolution cryo-EM structural analyses with molecular and cellular studies on RyR2 regulation, as well as clinical evidence of RyR2 mutations in arrhythmogenic heart diseases, we provide a comprehensive overview of the field. Cryo-EM has unraveled RyR2’s gating mechanisms, ligand-binding sites, and structural features. Functionally, RyR2 mediates calcium-induced calcium release (CICR) and maintains Ca2+ homeostasis through coordination with SERCA2a and NCX. Key modulators (CaM, FKBP12.6, and PKA/CaMKII) and disease-linked mutations regulate RyR2 activity through distinct pathways, with defective RyR2 leading to store-overload-induced Ca2+ release (SOICR) and arrhythmias. Furthermore, reactive oxygen species (ROS) can induce RyR2 oxidation, establishing a pathological Ca2+ leak-ROS cycle in heart disease. In conclusion, RyR2 is a pivotal sensor of myocardial function, with its structural and regulatory mechanisms now well-characterized by recent studies. However, the effects of numerous RyR2 mutations remain unclear, and deeper mechanistic insights will lay a key foundation for developing novel therapies against RyR2-related cardiac diseases.


  • Open Access

    NRF2-Targeted Therapy in Cardiovascular Disease Transitions from Systemic Activation to Precision Redox Medicine

    by Yizhao Peng, Jinhong Wei, Yang Yang

    The transcription factor Nuclear Factor Erythroid 2-Related Factor 2 (NRF2) governs cellular redox homeostasis and serves as a primary defense mechanism against oxidative stress-driven cardiac remodeling. Beyond basal antioxidant effects, NRF2 coordinates a broad defensive network that preserves mitochondrial bioenergetics, maintains proteostasis, and inhibits regulated cell death pathways, including necroptosis and ferroptosis. Despite robust efficacy in preclinical models, translating these findings to the clinic remains challenging. This review examines the molecular structure of the NRF2-KEAP1 axis, synthesizing evidence regarding its efficacy in ischemia–reperfusion injury and diabetic cardiomyopathy, while assessing the mechanisms of pathway repression and the liabilities of indiscriminate activation. We further review different pharmacological strategies, contrasting the clinical limitations of electrophiles with the potential of protein–protein interaction inhibitors. Finally, we discuss innovations such as cardiac-targeted delivery and biomarker-guided stratification, critically assessing whether these approaches can overcome safety barriers and emphasizing that rigorous validation is essential for clinical viability.


  • Open Access

    Inositol 1,4,5-Trisphosphate Receptor 1 Gain-of-Function Increases the Risk for Cardiac Arrhythmias in Mice and Humans

    by Bo Sun, Mingke Ni, Yanhui Li, Zhenpeng Song, Hui Wang, Hai-Lei Zhu, Jinhong Wei, Darrell Belke, Shitian Cai, Wenting Guo, et al.

    BACKGROUND: Ca 2+ mishandling in cardiac Purkinje cells is a well-known cause of cardiac arrhythmias. The Purkinje cell resident inositol 1,4,5-trisphosphate receptor 1 (ITPR1) is believed to play an important role in Ca 2+ handling, and ITPR1 gain-of-function (GOF) has been implicated in cardiac arrhythmias. However, nearly all known disease-associated ITPR1 variants are loss-of-function and are primarily linked to neurological disorders. Whether ITPR1 GOF has pathological consequences, such as cardiac arrhythmias, is unclear. This study aimed to identify human ITPR1 GOF variants and determine the impact of ITPR1 GOF on Ca 2+ handling and arrhythmia susceptibility. METHODS: There are a large number of rare ITPR1 missense variants reported in open data repositories. Based on their locations in the ITPR1 channel structure, we selected and characterized 33 human ITPR1 missense variants from open databases and identified 21 human ITPR1 GOF variants. We generated a mouse model carrying a human ITPR1 GOF variant, ITPR1-W1457G (W1447G in mice). RESULTS: We showed that the ITPR1-W1447G +/- and recently reported ITPR1-D2594K +/- GOF mutant mice were susceptible to stress-induced ventricular arrhythmias. Confocal Ca 2+ and voltage imaging in situ in heart slices and Ca 2+ imaging and patch-clamp recordings of isolated Purkinje cells showed that ITPR1-W1447G +/- and ITPR1-D2594K +/- variants increased the occurrence of stress-induced spontaneous Ca 2+ release, delayed afterdepolarization, and triggered activity in Purkinje cells. To assess the potential role of ITPR1 variants in arrhythmia susceptibility in humans, we looked up a gene-based association study in the UK Biobank data set and identified 7 rare ITPR1 missense variants showing potential association with cardiac arrhythmias. Remarkably, in vitro functional characterization revealed that all these 7 ITPR1 variants resulted in GOF. CONCLUSIONS: Our studies in mice and humans reveal that enhanced function of ITPR1 , a well-known movement disorder gene, increases the risk for cardiac arrhythmias.


  • Open Access

    Pleiotropic role of CCR9/CCL25 signaling in adriamycin-induced cardiomyopathy

    by Xue Wu, Zheng Wang, Zhenxing Liang, Ning Li, Junmin Chen, Qiong Liu, Wangrui Lei, Xiaopeng Wu, Chenxi Lu, Chao Deng, et al.


  • Increased Ca 2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction

    by Mingke Ni, Yanhui Li, Jinhong Wei, Zhenpeng Song, Hui Wang, Jinjing Yao, Yong-Xiang Chen, Darrell Belke, John Paul Estillore, Ruiwu Wang, et al.

    Background: A loss-of-function cardiac ryanodine receptor (RyR2) mutation, I4855M +/– , has recently been linked to a new cardiac disorder termed RyR2 Ca 2+ release deficiency syndrome (CRDS) as well as left ventricular noncompaction (LVNC). The mechanism by which RyR2 loss-of-function causes CRDS has been extensively studied, but the mechanism underlying RyR2 loss-of-function-associated LVNC is unknown. Here, we determined the impact of a CRDS-LVNC-associated RyR2-I4855M +/– loss-of-function mutation on cardiac structure and function. Methods: We generated a mouse model expressing the CRDS-LVNC-associated RyR2-I4855M +/– mutation. Histological analysis, echocardiography, ECG recording, and intact heart Ca 2+ imaging were performed to characterize the structural and functional consequences of the RyR2-I4855M +/– mutation. Results: As in humans, RyR2-I4855M +/– mice displayed LVNC characterized by cardiac hypertrabeculation and noncompaction. RyR2-I4855M +/– mice were highly susceptible to electrical stimulation–induced ventricular arrhythmias but protected from stress-induced ventricular arrhythmias. Unexpectedly, the RyR2-I4855M +/– mutation increased the peak Ca 2+ transient but did not alter the L-type Ca 2+ current, suggesting an increase in Ca 2+ -induced Ca 2+ release gain. The RyR2-I4855M +/– mutation abolished sarcoplasmic reticulum store overload–induced Ca 2+ release or Ca 2+ leak, elevated sarcoplasmic reticulum Ca 2+ load, prolonged Ca 2+ transient decay, and elevated end-diastolic Ca 2+ level upon rapid pacing. Immunoblotting revealed increased level of phosphorylated CaMKII (Ca 2+ -calmodulin dependent protein kinases II) but unchanged levels of CaMKII, calcineurin, and other Ca 2+ handling proteins in the RyR2-I4855M +/– mutant compared with wild type. Conclusions: The RyR2-I4855M +/– mutant mice represent the first RyR2-associated LVNC animal model that recapitulates the CRDS-LVNC overlapping phenotype in humans. The RyR2-I4855M +/– mutation increases the peak Ca 2+ transient by increasing the Ca 2+ -induced Ca 2+ release gain and the end-diastolic Ca 2+ level by prolonging Ca 2+ transient decay. Our data suggest that the increased peak-systolic and end-diastolic Ca 2+ levels may underlie RyR2-associated LVNC.


  • RyR2 Serine-2030 PKA Site Governs Ca 2+ Release Termination and Ca 2+ Alternans

    by Jinhong Wei, Wenting Guo, Ruiwu Wang, John Paul Estillore, Darrell Belke, Yong-Xiang Chen, Alexander Vallmitjana, Raul Benitez, Leif Hove-Madsen, S.R. Wayne Chen

    Background: PKA (protein kinase A)–mediated phosphorylation of cardiac RyR2 (ryanodine receptor 2) has been extensively studied for decades, but the physiological significance of PKA phosphorylation of RyR2 remains poorly understood. Recent determination of high-resolution 3-dimensional structure of RyR2 in complex with CaM (calmodulin) reveals that the major PKA phosphorylation site in RyR2, serine-2030 (S2030), is located within a structural pathway of CaM-dependent inactivation of RyR2. This novel structural insight points to a possible role of PKA phosphorylation of RyR2 in CaM-dependent inactivation of RyR2, which underlies the termination of Ca 2+ release and induction of cardiac Ca 2+ alternans. Methods: We performed single-cell endoplasmic reticulum Ca 2+ imaging to assess the impact of S2030 mutations on Ca 2+ release termination in human embryonic kidney 293 cells. Here we determined the role of the PKA site RyR2-S2030 in a physiological setting, we generated a novel mouse model harboring the S2030L mutation and carried out confocal Ca 2+ imaging. Results: We found that mutations, S2030D, S2030G, S2030L, S2030V, and S2030W reduced the endoplasmic reticulum luminal Ca 2+ level at which Ca 2+ release terminates (the termination threshold), whereas S2030P and S2030R increased the termination threshold. S2030A and S2030T had no significant impact on release termination. Furthermore, CaM–wild-type increased, whereas Ca 2+ binding deficient CaM mutant (CaM-M [a loss-of-function CaM mutation with all 4 EF-hand motifs mutated]), PKA, and Ca 2+ /CaMKII (CaM-dependent protein kinase II) reduced the termination threshold. The S2030L mutation abolished the actions of CaM–wild-type, CaM-M, and PKA, but not CaMKII, in Ca 2+ release termination. Moreover, we showed that isoproterenol and CaM-M suppressed pacing-induced Ca 2+ alternans and accelerated Ca 2+ transient recovery in intact working hearts, whereas CaM–wild-type exerted an opposite effect. The impact of isoproterenol was partially and fully reversed by the PKA inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline-sulfonamide and the CaMKII inhibitor N-[2-[N-(4-chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide individually and together, respectively. S2030L abolished the impact of CaM–wild-type, CaM-M, and N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline-sulfonamide–sensitive component, but not the N-[2-[N-(4-chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide–sensitive component, of isoproterenol.


  • Open Access

    Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome

    by Julian O.M. Ormerod, Elizabeth Ormondroyd, Yanhui Li, John Taylor, Jinhong Wei, Wenting Guo, Ruiwu Wang, Caroline N.S. Sarton, Karen McGuire, Helene M.P. Dreau, et al.

    Background: A novel familial arrhythmia syndrome, cardiac ryanodine receptor (RyR2) calcium release deficiency syndrome (CRDS), has recently been described. We evaluated a large and well characterized family to assess provocation testing, risk factor stratification and response to therapy in CRDS. Methods: We present a family with multiple unheralded sudden cardiac deaths and aborted cardiac arrests, primarily in children and young adults, with no clear phenotype on standard clinical testing. Results: Genetic analysis, including whole genome sequencing, firmly established that a missense mutation in RYR2 , Ala4142Thr, was the underlying cause of disease in the family. Functional study of the variant in a cell model showed RyR2 loss-of-function, indicating that the family was affected by CRDS. EPS (Electrophysiological Study) was undertaken in 9 subjects known to carry the mutation, including a survivor of aborted sudden cardiac death, and the effects of flecainide alone and in combination with metoprolol were tested. There was a clear gradation in inducibility of nonsustained and sustained ventricular arrhythmia between subjects at EPS, with the survivor of aborted sudden cardiac death being the most inducible subject. Administration of flecainide substantially reduced arrhythmia inducibility in this subject and abolished arrhythmia in all others. Finally, the effects of additional metoprolol were tested; it increased inducibility in 4/9 subjects. Conclusions: The Ala4142Thr mutation of RYR2 causes the novel heritable arrhythmia syndrome CRDS, which is characterized by familial sudden death in the absence of prior symptoms or a recognizable phenotype on ambulatory monitoring or exercise stress testing. We increase the experience of a specific EPS protocol in human subjects and show that it is helpful in establishing the clinical status of gene carriers, with potential utility for risk stratification. Our data provide evidence that flecainide is protective in human subjects with CRDS, consistent with the effect previously shown in a mouse model.


  • Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations

    by Yanhui Li, Jinhong Wei, Wenting Guo, Bo Sun, John Paul Estillore, Ruiwu Wang, Ayhan Yoruk, Thomas M. Roston, Shubhayan Sanatani, Arthur A.M. Wilde, et al.

    Background: The overall objective of the present study is to extend our understanding of the clinical phenotype and underlying mechanism of a newly discovered cardiac arrhythmia syndrome through a multicenter study. Gain-of-function mutations in the cardiac Ca 2+ release channel (RyR2 [ryanodine receptor 2]) cause catecholaminergic polymorphic ventricular tachycardia, whereas loss-of-function RyR2 mutations are linked to a new cardiac arrhythmia disorder termed Ca 2+ -release deficiency syndrome (CRDS). Catecholaminergic polymorphic ventricular tachycardia is an inherited arrhythmia disorder characterized by stress-induced bidirectional and polymorphic ventricular tachyarrhythmias and is routinely diagnosed by using exercise stress testing. Conversely, RyR2-CRDS is characterized by ventricular arrhythmias and sudden cardiac death but a negative exercise stress testing for catecholaminergic polymorphic ventricular tachycardia. There are currently no clinical diagnostic tests for CRDS and affected patients may manifest with sudden cardiac death as their first symptom. In the absence of effective clinical diagnostic tools, in vitro functional characterization of associated RyR2 mutations provides an alternative means to identify potential cases of CRDS. Methods: We searched for patients presenting with phenotypes compatible with CRDS that have RyR2 mutations and performed in vitro functional characterization. Results: We found that 3 novel (G570D, R4147K, and A4203V) and 2 previously reported (M4109R and A4204V) RyR2 mutations associated with CRDS phenotypes markedly reduced caffeine-induced Ca 2+ release and store overload-induced Ca 2+ release. We also characterized 2 additional loss-of-function RyR2 mutations previously reported (Q3925E and L4769S) that are located in the central and channel pore-forming domains critical for Ca 2+ activation and channel gating. Q3925E was identified through postmortem genetic testing in an individual who died suddenly, while L4769S is a variant of uncertain significance reported in ClinVar, suggesting that RyR2 CRDS may be under detected. Conclusions: These findings provide further support for the existence of an emerging RyR2 loss-of-function associated arrhythmia syndrome (CRDS) and shed new insights into the disease mechanism.


  • Open Access

    Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias

    by Zhichao Xiao, Wenting Guo, Bo Sun, Donald J. Hunt, Jinhong Wei, Yingjie Liu, Yundi Wang, Ruiwu Wang, Peter P. Jones, Thomas G. Back, et al.